Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.

  title={Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.},
  author={Herbert Schuster and Jonathan C Fox},
  journal={Expert opinion on pharmacotherapy},
  volume={5 5},
The GALAXY Programme is a comprehensive global research initiative that will address several important unanswered questions in statin research and investigate the impact of rosuvastatin on cardiovascular risk reduction and patient outcomes. Studies already completed demonstrate that rosuvastatin provides greater reductions in low-density lipoprotein cholesterol (LDL-C) than other statins, enabling more patients to achieve LDL-C treatment goals. Additionally, rosuvastatin provides beneficial… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…